Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics, Inc. (SPTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Announced positive topline data from Phase 1 driving simulation trial of GlyphAllo TM , showing that GlyphAllo did not impair next-morning driving
How this was made
The 30-second read
Why it matters
The disclosed data reduces development risk and extends cash runway, likely prompting short‑term buying interest.
Market read
First‑hand disclosure of trial progress and financial health provides fresh material for traders in the biotech space.
What to watch
Upcoming regulatory review timelines and competition from larger neuropsychiatric players
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport advanced two Phase 2 programs, reported positive Phase 1 driving-simulation data for GlyphAllo, maintained BUOY-1 enrollment and a 1H 2027 topline-data timeline, and reported cash, cash equivalents and investments expected to fund current operating plans into 2029. Quarterly R&D, G&A and net loss increased year over year as development activity and public-company costs rose.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended September 30, 2026GAAP | $23.89M | – | increase of $3.4 million |
| Research and development non-cash stock-based compensation expense, three months ended September 30, 2026GAAP | $1M | – | – |
| General and administrative expenses, three months ended September 30, 2026GAAP | $6.45M | – | increase of $1.5 million |
| General and administrative non-cash stock-based compensation expense, three months ended September 30, 2026GAAP | $1.5M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $30.34M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$30.34M | – | – |
| Total other income (expense), net, three months ended September 30, 2026GAAP | $4.08M | – | – |
| Loss before income taxes, three months ended September 30, 2026GAAP | −$26.27M | – | – |
| Income tax provision, three months ended September 30, 2026GAAP | $127K | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$26.39M | – | – |
| Net loss per share, basic and diluted, three months ended September 30, 2026GAAP | $ (0.49 ) | – | – |
| Weighted-average common shares outstanding, basic and diluted, three months ended September 30, 2026GAAP | 53,530,550 | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $69.94M | – | – |
| Research and development non-cash stock-based compensation expense, nine months ended September 30, 2026GAAP | $2.7M | – | – |
| General and administrative expenses, nine months ended September 30, 2026GAAP | $53.76M | – | – |
| General and administrative non-cash stock-based compensation expense, nine months ended September 30, 2026GAAP | $39.1M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $123.7M | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$123.7M | – | – |
| Total other income (expense), net, nine months ended September 30, 2026GAAP | $10.19M | – | – |
| Loss before income taxes, nine months ended September 30, 2026GAAP | −$113.5M | – | – |
| Income tax provision, nine months ended September 30, 2026GAAP | $898K | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$114.4M | – | – |
| Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP | $ (3.72 ) | – | – |
| Weighted-average common shares outstanding, basic and diluted, nine months ended September 30, 2026GAAP | 30,714,936 | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Into 2029 and upcoming clinical milestones outlook
- NoteCash, cash equivalents, and investments are expected to support current operating plans into 2029.
- NoteTopline data from the GlyphAllo Phase 2b BUOY-1 trial are expected in the first half of 2027.
- NoteThe Company plans to initiate the GlyphAgo Phase 2/3 trial in the first half of 2027.
- NoteTopline data from the GlyphAgo Phase 2a trial are expected in early 2028.
- NoteTopline data from the GlyphAgo Phase 2/3 trial are expected by year-end 2028.
- NoteCompletion of first-in-human-enabling studies for Glyph2BLSD is expected by year-end 2027.
What drove it
- R&D expenses increased primarily due to increases in clinical development expenses related to advancement of the Phase 2b BUOY-1 trial of GlyphAllo.
- G&A expenses increased primarily due to increased costs related to operating as a public company.
- The Phase 1 driving simulation trial met its primary endpoint: evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5 following multiple-day dosing.
- The key secondary endpoint was met: a single evening dose of 250 mg GlyphAllo did not impair next-morning driving performance compared to placebo on Day 2.
- GlyphAgo Phase 1 pharmacokinetic data showed a statistically significant 6.8-fold increase in agomelatine bioavailability and substantially lower (10-fold) PK variability compared to unmodified agomelatine.
Concerns
- Net loss was $ (26,394 ) (In thousands) for the three months ended September 30, 2026, compared with $ (22,544 ) (In thousands) for the three months ended September 30, 2025.
- R&D expenses were $ 23,891 (In thousands) for the three months ended September 30, 2026, compared with $ 20,453 (In thousands) for the three months ended September 30, 2025.
- G&A expenses were $ 6,454 (In thousands) for the three months ended September 30, 2026, compared with $ 4,988 (In thousands) for the three months ended September 30, 2025.
- The filing states that results from earlier trials, including Phase 1 trials, may not be predictive of future results and that interim results may not be predictive of final clinical-trial results.
What to watch
- Topline data from the GlyphAllo Phase 2b BUOY-1 trial in the first half of 2027.
- Initiation of the potentially registration-enabling GlyphAgo Phase 2/3 trial in the first half of 2027.
- Topline data from the GlyphAgo Phase 2a proof-of-pharmacology trial in early 2028.
- Topline data from the GlyphAgo Phase 2/3 trial by year-end 2028.
- Completion of first-in-human-enabling studies for Glyph2BLSD by year-end 2027.
- The FDA's review of the GlyphAllo Phase 1 driving simulation trial results.
Balance sheet and cash flow
- Cash, cash equivalents and investments: $ 403,799 (In thousands) as of September 30, 2026, compared with $ 233,653 (In thousands) as of December 31, 2025.
- Working capital: $ 281,956 (In thousands) as of September 30, 2026, compared with $ 210,448 (In thousands) as of December 31, 2025.
- Total assets: $ 417,624 (In thousands) as of September 30, 2026, compared with $ 249,009 (In thousands) as of December 31, 2025.
- Total stockholders' equity (deficit): $ 397,455 (In thousands) as of September 30, 2026, compared with $ (92,545 ) (In thousands) as of December 31, 2025.
Analysis
Seaport remains a clinical-stage company and did not report revenue. Its quarter centered on execution across its two Phase 2 programs. The company reported positive Phase 1 driving-simulation data for GlyphAllo, with the 375 mg multiple-dose primary endpoint and 250 mg single-dose key secondary endpoint showing no next-morning driving impairment versus placebo. It also dosed the first patient in the GlyphAgo Phase 2a proof-of-pharmacology trial.
The GlyphAllo program's key near-term event is topline data from the Phase 2b BUOY-1 trial in MDD, expected in the first half of 2027. Management stated that enrollment is on track. For GlyphAgo, Seaport plans to initiate a potentially registration-enabling Phase 2/3 GAD trial in the first half of 2027, while Phase 2a data are expected in early 2028 and Phase 2/3 data are expected by year-end 2028.
Quarterly operating costs rose alongside pipeline activity. R&D expenses were $ 23,891 (In thousands), versus $ 20,453 (In thousands), with the company attributing the increase primarily to clinical-development expenses for BUOY-1. G&A expenses were $ 6,454 (In thousands), versus $ 4,988 (In thousands), primarily reflecting public-company operating costs. Total operating expenses were $ 30,345 (In thousands), and net loss was $ (26,394 ) (In thousands), compared with $ (22,544 ) (In thousands) in the prior-year quarter.
Liquidity is the principal financial support for the stated development plan. Cash, cash equivalents and investments were $ 403,799 (In thousands) as of September 30, 2026, compared with $ 233,653 (In thousands) as of December 31, 2025. The company expects these resources to support its current operating plans into 2029, through three upcoming mid-to-late-stage clinical data readouts. No operating cash flow, free cash flow, debt balance, repurchases, dividends, revenue, or financial revenue guidance was reported.
The most consequential milestones are BUOY-1 topline data in the first half of 2027 and the planned start of the GlyphAgo Phase 2/3 trial in the first half of 2027. The filing also identifies FDA review of the submitted GlyphAllo driving-study results, later GlyphAgo readouts in 2028, and completion of Glyph2BLSD first-in-human-enabling studies by year-end 2027 as additional program milestones. The company notes that earlier-trial results may not predict future outcomes and that clinical, regulatory, funding and execution risks remain.
Management, verbatim
Over the last few months, Seaport met two key clinical milestones – we dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance, and demonstrated that GlyphAllo did not impair next-morning driving performance in a Phase 1 driving trial.
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
Seaport is well-capitalized, with cash runway through all three of our upcoming mid-to-late-stage clinical data readouts.
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
Not in the filing
stated, not guessed- Revenue and revenue growth were not reported.
- Segment revenue and segment profitability were not reported.
- Gross profit, gross margin, operating margin and net margin were not reported.
- Non-GAAP financial measures were not reported.
- Operating cash flow, capital expenditures and free cash flow were not reported.
- Debt and other liability balances were not reported.
- Share repurchases, dividends and other capital-return activity were not reported.
- A prior-quarter comparison for reported financial metrics was not reported.
- Financial revenue, gross-margin, operating-expense or tax-rate guidance was not reported.
- Previous-release outlook was not provided, so comparison with prior guidance is unavailable.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Seaport Therapeutics filed a Form 8‑K reporting its Q3 2026 financials and recent clinical milestones for GlyphAllo and GlyphAgo programs.
Ticker impact
SEC 8‑K disclosed Q3 2026 results and positive Phase 1 driving‑simulation data for GlyphAllo, plus first patient dosed in Phase 2a GlyphAgo trial.
likely upward pressure as investors price in successful Phase 1 results and robust cash runway
Phase 1 trial met primary endpoint and Phase 2a enrollment began; biotech stocks typically rally on such milestones.
Market effects
strengthens outlook for neuropsychiatric biotech sector as early data de‑risk pipelines
minimal regional effect; impact confined to US biotech investors
limited to global biotech investors tracking mental‑health drug development
Counterpoint
Phase 1 data may not translate to later‑stage success; cash burn could increase if trials delay
Key entities
- companySeaport Therapeutics
Clinical‑stage biotech developing neuropsychiatric medicines
